Floatz logo

muc1 peptide-poly-iclc adjuvant vaccine

Inflammatory Breast Cancer

Joseph Baar, MD, PhDvaccineEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Inflammatory Breast Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
TRASTUZUMAB
Hoffmann-La Roche
Phase 3BBB
Cyclophosphamide
Northwestern University
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

muc1 peptide-poly-iclc adjuvant vaccine is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
breast cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →